ENTX logo

ENTERA BIO LTD

ENTXNASDAQ
🏆 #2817 by market capUS Equity
$3.10—
Last available close · quote unavailable
🔔
Track ENTX
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▲ 2.5%
14d▲ 11.7%
30d▲ 15.5%
ytd▲ 63.8%
1y▲ 14.6%
🏦Market Cap
$532M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
4.0%
Thin
💵FCF Margin
—
⚖️P/S Ratio
2402.2x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$0.91 – $4.20
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
173.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$42,000
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
2402.2x
EPS (TTM)
$-0.35
Dividend Yield
—
Dilution (1yr)
+22.7%
ENTX logo

ENTERA BIO LTD

ENTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$42K▼ −76.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
0.0%▼ −100.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$12M▲ +20.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▲ +9.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.2M▲ +22.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▼ −$2M YoY
StockOtter · stockotter.space

About ENTERA BIO LTD

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.